vrtx nasdaq - Search News

Vertex Pharmaceuticals, NASDAQ

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 billion. The company expects the full year’s revenue to be around $11.88 billion,

YAHOO!Finance · 20h

Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 50% Above Its Share Price

In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.

The Motley Fool on MSN · 13h

Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a listen-only mode. [Operator instructions] Please note, this event is being recorded.

Zacks.com on MSN · 12h

Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago. These figures are adjusted for non-recurring items.

Nasdaq5d

Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?

Vertex Pharmaceuticals Incorporated VRTX will report fourth-quarter and full-year 2024 earnings result on Feb. 10, after market close. The Zacks Consensus Estimate for sales and earnings for the ...

20m

Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

10h

Vertex's Revenue Surges but EPS Slips

Vertex provided a revenue guidance range of $11.75 billion to $12 billion for 2025, which would amount to an increase of 6.6% to 8.9%. Management anticipates continued strong performance from its ...

Nasdaq8d

Should You Pick VRTX Stock At $450?

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results